Evelo Biosciences Inc
NASDAQ:EVLO
Evelo Biosciences Inc
Net Change in Cash
Evelo Biosciences Inc
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Evelo Biosciences Inc
NASDAQ:EVLO
|
Net Change in Cash
-$52.2m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$218m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$126.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Evelo Biosciences Inc's Net Change in Cash?
Net Change in Cash
-52.2m
USD
Based on the financial report for Sep 30, 2023, Evelo Biosciences Inc's Net Change in Cash amounts to -52.2m USD.
What is Evelo Biosciences Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-50%
Over the last year, the Net Change in Cash growth was -93%. The average annual Net Change in Cash growth rates for Evelo Biosciences Inc have been -50% over the past three years .